Basiliximab and infliximab for the treatment of steroid-refractory Crohn's disease.

Price, Michelle; Probert, Christopher S J; Creed, Tom

Price, Michelle; Probert, Christopher S J; Creed, Tom.

Am J Gastroenterol ; 103(10): 2665, 2008 Oct.

Article in En | MEDLINE | ID: mdl-18855871

Subject(s)

Antibodies, Monoclonal/administration & dosage; Crohn Disease/drug therapy; Drug Resistance; Glucocorticoids/pharmacology; Recombinant Fusion Proteins/administration & dosage; Adult; Basiliximab; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Agents/administration & dosage; Humans; Immunosuppressive Agents/administration & dosage; Infliximab

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Recombinant Fusion Proteins / Drug Resistance / Crohn Disease / Glucocorticoids / Antibodies, Monoclonal Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans Language: En Journal: Am J Gastroenterol Year: 2008 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google